The Art of
Licensing 		The Art of
Development 		The Art of
Access 		The Art of
Manufacturing 		The Art of
Partnership
Home > The Art of Licensing > About Helsinn > News
News
16.05.2013Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Netupitant and Palonosetron for Prevention of CINV
16.05.2013Helsinn and Vifor Pharma sign Licensing and Distribution agreement for Netupitant-Palonosetron fixed dose combination
22.04.2013Helsinn and DARA Announce U.S. Launch of Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis
03.04.2013Helsinn Group enters into a new partnership with Healthcare Businesswomen’s Association (HBA)
01.03.2013Joseph Hogan, new Vice President of Sales and Marketing at Helsinn Therapeutics, U.S. subsidiary of Helsinn Group
29.01.2013HELSINN GRANTS STENDHAL RIGHTS TO ANAMORELIN, A FIRST-IN-CLASS COMPOUND TO TREAT CACHEXIA-ANOREXIA RELATED TO NON-SMALL CELL LUNG CANCER (NSCLC)
08.01.2013CEO's Newsletter: "The importance of Health Quality of Life in Cancer at Helsinn" - “L'importanza per Helsinn della Qualità della Vita Correlata alla Salute dei pazienti oncologici”
07.01.2013Helsinn at the 31st Annual J.P. Morgan Healthcare Conference, January 8, 2013
12.12.2012ASCO Secures Major Funding and Data License Agreements for CancerLinQ™, a “Rapid Learning” System to Transform Cancer Care and Speed the Search for Cures
11.12.2012PALONOSETRON INFUSION BAG LAUNCHED IN JAPAN
13.11.2012Helsinn Group, Switzerland Announces Support of CancerLinQ™
29.10.2012RICCARDO BRAGLIA - BEST SWISS ENTREPRENEUR OF THE YEAR 2012
22.10.2012CEO's Newsletter: Fine Chemicals in Helsinn: shaping quality services and building innovative pharmaceutucal active ingredients .... Chimica fine in Helsinn disegnando servizi di qualità e creando principi attivi innovativi ...
15.10.2012Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)
01.10.2012Oral Palonosetron Shows Safe and Effective Control of Nausea and Vomiting Induced by Multiple Cycles of Chemotherapy
24.09.2012HELSINN GROUP, SWITZERLAND ANNOUNCES A LICENSE AGREEMENT FOR NETUPITANT - PALONOSETRON FIXED DOSE COMBINATION WITH CJ CHEILJEDANG, SOUTH KOREA FOR KOREA
13.09.2012HELSINN GRANTS TO DARA EXCLUSIVE U.S. COMMERCIAL RIGHTS TO GELCLAIR®, AN FDA-CLEARED ORAL GEL FOR THE TREATMENT OF ORAL MUCOSITIS
31.07.2012THORNE RESEARCH, INC. AND HELSINN HEALTHCARE SA, ANNOUNCE ONCOQOL (TM)
22.07.2012CEO's Newsletter: Licensing: the strength of our model of doing business, the professionalis of making it unique ... Licensing: la forza del nostro modello di fare business, la professionalità di renderlo unico ....
16.07.2012HELSINN PARTNERS WITH THE EUROPEAN SCHOOL OF ONCOLOGY (ESO)
02.03.2012Helsinn and Zealand Pharma announce the advance of elsiglutide into Phase II for the prevention of chemotherapy-induced diarrhea in cancer patients
07.12.2011Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
27.09.2011Helsinn and Riemser Extend Relationship in Germany
26.09.2011HELSINN GROUP IS REINFORCING ITS CANCER SUPPORTIVE CARE PIPELINE
23.08.2011Helsinn Therapeutics Initiates Global Pivotal Phase III Clinical Program to Evaluate Anamorelin in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
17.08.2011HELSINN GROUP EXTENDS COLLABORATION WITH SPECIALISED THERAPEUTICS AUSTRALIA
07.07.2011Palonosetron Better Prevents Nausea and Vomiting Linked to High Emetogenic Chemotherapy Lung Cancer Patients
27.06.2011Nimesulide: European Medicines Agency concludes positive review under Article 31 of Directive 2001/83/EC
11.05.2011HELSINN GROUP INVESTS IN THORNE RESEARCH AND WILL JOINTLY PURSUE THE DEVELOPMENT OF NUTRITIONAL PRODUCTS, INFORMATION AND SUPPORT SERVICES IN CANCER CARE
13.04.2011Helsinn and Taiho Pharmaceutical Co., Ltd. to Extend Relationship
01.04.2011THE HELSINN GROUP BRACES BIASCA - IL GRUPPO HELSINN PUNTA SU BIASCA
02.03.2011Big Plans for New Cytotoxic Plant - New Cytotoxic Plant will be a Dedicated Facility at Helsinn Advanced Synthesis SA
02.02.2011Helsinn Receives Scientific Advice from European Medicines Agency Supporting Phase III Trial Program of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV
12.01.2011FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV
10.01.2011Helsinn Healthcare SA and IS Pharma Announce Strategic Alliance
22.12.2010HELSINN BIREX PHARMACEUTICALS LIMITED HAS BEEN ASSIGNED CERTAIN INTERNATIONAL RIGHTS TO KLEAN-PREP® BY HELIX BIOPHARMA CORP.
09.11.2010HELSINN GRANT TO THE ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND (IOSI) - CONTRIBUTO HELSINN PER L’ISTITUTO ONCOLOGICO DELLA SVIZZERA ITALIANA (IOSI)
02.11.2010HELSINN ANNOUNCES LICENSE AGREEMENT WITH SPECIALISED THERAPEUTICS FOR ALOXI® (PALONOSETRON) IN AUSTRALIA
11.10.2010PALONOSETRON MORE EFFECTIVE THAN GRANISETRON IN CONTROLLING NAUSEA ACCORDING TO THE PROTECT STUDY
01.09.2010HELSINN ANNOUNCES THE OFFICIAL OPENING OF ITS NEW R&D CENTRE OF EXCELLENCE IN DUBLIN
08.07.2010HELSINN AND MUNDIPHARMA SIGN NEW CONTRACT FOR PALONOSETRON IN ASIAN COUNTRIES
09.06.2010Helsinn Healthcare S.A. and Eisai Inc. Extend Relationship
26.04.2010HELSINN AND VIFOR PHARMA SIGN NEW CONTRACT FOR GELCLAIR IN SWITZERLAND

2013

2012

2011

2010

2009
 
Home
Legal Statement
News
Contacts
Sitemap
Document Central
Jobs
Helsinn′s Board of Directors and Top Management
Links
Printer Friendly
Copyright © Helsinn Group - Legal Statement
Last Update: 16.05.2013
Free acces to Helsinn newsletter
Subscribe  or Unsubscribe
About Helsinn Our Products Our Partners